Key Points for Decision Makers {#FPar1}
==============================

In this literature review, non-treatment of patients with anaemia of chronic kidney disease (CKD) who were not on dialysis resulted in higher costs and was associated with poorer health-related quality of life (HRQoL), which emphasizes the need for treatment.However, aiming for haemoglobin targets \>12 g/dL led to seemingly modest HRQoL improvements of uncertain clinical significance. Improvements in the vitality domain appeared more robust than those in other domains.Effective treatment options with improved safety profiles are needed to improve the HRQoL of these patients with anaemia of CKD.

Introduction {#Sec1}
============

Chronic kidney disease (CKD) is defined by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines as "abnormalities of kidney structure or function, present for \> 3 months, with implications for health" \[[@CR1]\]. With a prevalence of 3--18% globally \[[@CR2]\], CKD is an important public health problem associated with high rates of mortality and disability. The disease is caused by the progressive loss of kidney function and consequential accumulation of uremic toxins, which can ultimately lead to the requirement for kidney-replacement therapy (KRT; i.e. dialysis or kidney transplant), generally when glomerular filtration rate falls below 15 mg/dL \[[@CR1], [@CR3], [@CR4]\]. There are few therapies that can reverse disease progression, and 3-year survival following diagnosis of end-stage renal disease (ESRD) is only 57% and 68% among haemodialysis and peritoneal dialysis patients, respectively \[[@CR5]\]. Kidney transplantation, the preferred treatment for patients with ESRD, involves a long wait or is not always an option: in 2015 in the USA, 99,120 patients were waiting for kidney transplants, yet only 18,805 kidney transplants were performed in the USA in that year. The median wait time for an individual's first kidney transplant is 3.9 years \[[@CR6]\]. Therefore, the proactive treatment and preservation of kidney function are of utmost importance in pre-dialysis patients.

The cost and health-related quality of life (HRQoL) burden of patients with non-dialysis-dependent (NDD) CKD increase substantially with disease progression while maintaining better overall HRQoL \[[@CR7]--[@CR9]\] and incurring lower costs \[[@CR10]\] than dialysis-dependent (DD) patients. In the USA, the prevalence of CKD stage 1--4 is estimated at 30 million individuals and that of patients with DD-CKD at 500,000. As many as 70% of affected individuals could be undiagnosed and remain in primary care \[[@CR11]\]. In the USA in 2012, the average Medicare-insured patient with stage 1--2 CKD incurred annual healthcare costs estimated at \$US17,969, and those with CKD stage 3 incurred costs of \$US19,392 \[[@CR12]\]. Among privately insured patients, annual costs are estimated to be approximately \$US10,000--12,000 per patient \[[@CR8]\]. Due to the high number of patients affected and the associated costs, NDD-CKD imposes a heavy burden on healthcare systems.

Diagnosis of CKD may be prompted by patient-reported fatigue (or other symptoms) caused by anaemia, which is a significant contributor to the burden of CKD. Other patient-reported symptoms such as reduced mental activity, insomnia, and reduced libido have also been attributed to anaemia and contribute to reducing the quality of life of this patient population in CKD \[[@CR13]--[@CR18]\]. Anaemia affects 8.4% of patients with CKD stage 1, increasing to 53.4% for patients with CKD stage 5 \[[@CR19]\]. Current therapies for anaemia of CKD include iron replacement, erythropoiesis-stimulating agents (ESAs), and/or red blood cell transfusions (RBCTs), the latter being used almost always as a rescue therapy. In NDD patients not on iron or ESA therapy, a trial of intravenous iron is recommended by current guidelines \[[@CR20]\]. Furthermore, ESAs are not recommended in this population unless haemoglobin levels fall below a threshold of 10.0 g/dL \[[@CR20]\]. The clinical utility of ESAs is dependent on balancing their efficacy with the concerns of increased risks of major adverse cardiovascular events (MACE) \[[@CR20]--[@CR24]\], and the fact that nearly 10% of patients are ESA-hyporesponsive. Their prohibitive cost forms an additional barrier that hinders access to this treatment class for many patients. Therefore, for a large number of patients with NDD-CKD, treatment with ESAs is ineffective, insufficient, inaccessible, or contraindicated as the benefits of ESAs do not outweigh their potential risks.

Based on these limitations, clinical practice guidelines, as well as US and European regulatory agencies, usually recommend against intentionally aiming for haemoglobin treatment targets above 11.5 g/dl and discourage exceeding the 13 g/dL threshold with ESAs in NDD- and DD-CKD \[[@CR20], [@CR25]--[@CR28]\]. This relatively recent recommendation included in updated guidelines caused a reduction in the proportion of patients with NDD-CKD using ESAs from 2009 to 2013 \[[@CR29], [@CR30]\]. Regional disparities in the real-world clinical management of anaemia of CKD do exist, as exemplified by the fact that higher haemoglobin levels are achieved by real-world patients in regions such as Japan, Brazil, and Europe relative to patients in the USA \[[@CR31]\]. Thus, having an updated global assessment of the outcomes related to the treatment of anaemia of CKD is warranted.

Four systematic literature reviews (SLRs) published between 2010 and 2017 reviewed the cost burden and/or HRQoL of anaemia of CKD \[[@CR32]--[@CR35]\]. However, three of them were restricted to specific geographic areas or did not focus on patients with NDD-CKD \[[@CR32], [@CR33], [@CR35]\], and the fourth studied the impact of ESAs on HRQoL based only on data from prospective randomized trials that included DD patients \[[@CR34]\]. The 2010 review by van Nooten et al. \[[@CR33]\] concluded that the evidence on the economic and HRQoL burden in NDD-CKD is limited but nonetheless substantial. Because randomized controlled trials (RCTs) are conducted in highly controlled settings that may significantly differ from real-world clinical practice, the applicability of RCT findings to the real world could be limited. In addition, periodically reassessing the economic value of treating anaemia of CKD is necessary, as evidenced by the drastic change in epoetin alfa's cost effectiveness from 1990 to 2000 \[[@CR36]\]. Therefore, to provide an updated and global perspective on the economic burden and HRQoL outcomes of anaemia of CKD, we conducted a systematic review of the literature on the costs and HRQoL associated with current treatments for anaemia of CKD among patients with NDD-CKD and included real-world studies in addition to RCTs.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

Electronic databases, including the Cochrane Library, MEDLINE (including MEDLINE In-Process), Embase, National Institute for Health Research Economic Evaluation Database (NHS EED), and National Institute for Health Research-Health Technology Assessment (NHS HTA), were searched on 17 March 2017 to identify relevant publications in English.

Literature Search Strategy and Study Selection Process {#Sec4}
------------------------------------------------------

Studies were required to meet the following criteria: adult population (i.e. at least one patient aged ≥ 18 years); disease area was anaemia of CKD; iron/ferric supplementation, RBCT, or ESAs (i.e. epoetin or darbepoetin) were among the included treatments; study population was NDD (or, if both DD and NDD patients were included, outcomes were presented separately for NDD patients); and costs and/or HRQoL were among the outcomes investigated (Appendix [1](#Sec22){ref-type="sec"}).

Cost outcomes included healthcare resource utilization (HRU), direct costs, and indirect costs. An HRU outcome corresponded to any measurement of the healthcare resources used by patients, which included medical visits (inpatient and outpatient) and use of rescue therapies (e.g. RBCT). Direct costs corresponded to costs paid by payers or to patients' out-of-pocket costs, such as drug costs or medical visits. Indirect costs corresponded to costs ensuing from a patient's inability to perform normal daily activities, such as work (i.e. loss of productivity costs).

Exclusion criteria included strictly paediatric population (i.e. all patients aged \< 18 years); study population was non-human (i.e. animal or cell-based studies); publication was a letter, editorial, comment, case report, biography, or address (i.e. not a study in which new results were generated); article was not in English; article was published before 1 January 2000. Studies that did not allow for the evaluation of incremental cost or HRQoL outcomes from a particular treatment (i.e. head-to-head comparisons between different treatments, dose-escalation studies, treatment switch studies, programme evaluation studies, etc.) were also excluded. This is because the design of these studies could not help achieve the objective of the current study.

The study selection process was conducted in two steps (Fig. [1](#Fig1){ref-type="fig"}). First, titles and abstracts were screened by two independent reviewers (SR, L-AD \[acknowledged\], or FK-K \[acknowledged\]) for eligibility based on the aforementioned inclusion and exclusion criteria. Discrepancies in the decisions were resolved through discussion, and a third reviewer (PT-L) was consulted whenever consensus was not reached. Second, two independent reviewers (SR, L-AD, or FK-K) reviewed the full texts of studies retained in the prior step to determine their eligibility based on the same aforementioned eligibility criteria. Disagreements in decisions were resolved through discussion. When consensus was not reached, a third independent reviewer (PT-L) was consulted.Fig. 1The PRISMA statement flow diagram. *CKD* chronic kidney disease, *HRQoL* health-related quality of life

Data Extraction {#Sec5}
---------------

Two independent reviewers (from MarksMan Healthcare Solutions LLP) extracted data from the full publications. Discrepancies were resolved through discussion. Contingent on availability, select variables were extracted from the included publications and recorded in an Excel spreadsheet (Appendix [2](#Sec23){ref-type="sec"}).

Analysis {#Sec6}
--------

Because study designs and outcomes were anticipated to be heterogeneous, a meta-analysis was not expected to be feasible; thus, results were summarized in a narrative synthesis. Although the clinical significance of HRQoL findings was often not assessed using minimal clinically meaningful differences (MCIDs), results were compared with MCID thresholds found in the literature (Appendix [3](#Sec24){ref-type="sec"}). Costs and cost differences were extracted as reported without currency standardization or adjustment for inflation.

Results {#Sec7}
=======

Search Results {#Sec8}
--------------

In total, 1625 unique publications were retrieved from the electronic search strategy. After screening by titles and abstracts, 418 (25.7%) full-length publications were assessed for eligibility. Of these, 30 (7.2%) met inclusion criteria. After eliminating studies that did not allow for the evaluation of incremental cost or HRQoL outcomes from a particular treatment, 16 (53.3%) were included in the current analysis (Fig. [1](#Fig1){ref-type="fig"}). Most studies (12 of 16 \[75.0%\]) were based on data collected before 2011 \[[@CR16], [@CR23], [@CR37]--[@CR46]\].

Study Designs and Outcomes {#Sec08}
--------------------------

Six (37.5%) RCTs \[[@CR23], [@CR37], [@CR40], [@CR47]--[@CR49]\], four (25.0%) prospective single-arm trials \[[@CR38], [@CR44]--[@CR46]\], three (18.8%) retrospective studies \[[@CR41]--[@CR43]\], one (6.3%) prospective observational study \[[@CR16]\], one (6.3%) simulation study \[[@CR39]\], and one (6.3%) cross-sectional survey \[[@CR14]\] were included (Fig. [2](#Fig2){ref-type="fig"}). Included studies comprised four (25.0%) real-world studies \[[@CR16], [@CR41]--[@CR43]\], none of which had data collected prior to 2011. Cost outcomes were reported in three (18.8%) articles \[[@CR41]--[@CR43]\], HRQoL outcomes were reported in ten (62.5%) articles \[[@CR14], [@CR16], [@CR37], [@CR38], [@CR40], [@CR44], [@CR45], [@CR47]--[@CR49]\], and both costs and HRQoL outcomes were reported in three (18.8%) articles (Table [1](#Tab1){ref-type="table"}) \[[@CR23], [@CR39], [@CR46]\].Fig. 2Number of included studies by study designTable 1Summary of included articlesStudy, year of publication, countryHRQoLCostsSample sizeDuration of follow-upTreatment(s)Hb target(s)Mean Hb levels achievedStudy designAkizawa et al. \[[@CR37]\], 2011, Japanx32112 weeks (HRQoL assessment)• Darbepoetin α (Hb target 11.0--13.0 g/dL);• RHuEPO (low Hb target 9.0--11.0 g/dL)Target achieved in both groups, but exact value not providedRCTClement et al. \[[@CR39]\], 2010, CanadaxxAKDN: 438Cohort (AKDN): 42 monthsESAs (type not specified)• No ESA• Low (Hb 9--10.9 g/dL)• Intermediate (Hb 11--12 g/dL)• High (Hb \> 12 g/dL)NA (simulation study)Simulation studyDe Goeij et al. \[[@CR38]\], 2014, Netherlandsx371Follow-up period not standardized for all patients, HRQoL assessed at 6-month intervals• ESA• Epoetin• Darbepoetin• Rron• ESA/ironNA (not specified)NA (Hb groups compared at a single time point)Prospective single-arm trial, cohort studyEriksson et al. \[[@CR14]\], 2016, France, Germany, Italy, Spain and UKx2898NA (cross-sectional study)• Patients treated with ESA and/or iron• Patients without ESA and/or ironNA (cross-sectional study)Hb levels (non-dialysis): 11.5 g/dLCross-sectional surveyFinkelstein et al. \[[@CR16]\], 2009, USA, Canadax1186NA (cross-sectional study)Patients with Hb levels• \< 11 g/dL• 11--12 g/dL• 12--13 g/dL• ≥ 13 g/dLNA (not specified)NA (only proportions of patients in different Hb groups reported)Prospective observational, cohort studyHirakata et al. \[[@CR40]\], 2009, Japanx17116 weeks (HRQoL assessment)• Darbepoetin α (Hb target = 12--13 g/dL)• Epoetin α (Hb target = 10--12 g/dL)NB: HRQoL assessment was performed before patients had different Hb targets (relative to baseline)At 48 weeks:• Hb (darbepoetin α): 11.75 g/dL• Hb (epoetin α): 10.42 g/dLRCTIslam et al. \[[@CR45]\], 2005, Bangladeshx453 months (HRQoL assessment)rHuEpo/EPO• Hb = 11.0 g/dL• Hb levels: at 3 months 9.5 g/dL• Hb levels at 6 months 11.1 g/dLProspective single-arm trial, cohort studyKawaguchi et al. \[[@CR44]\], 2004, Japanx258 months (HRQoL assessment)• SC epoetin-β• Hb = 11--12 g/dLTarget achieved, but exact value not providedProspective single-arm trial, cohort studyLewis et al. \[[@CR47]\], 2011, Canada, Italy, UK, and USAx403897 weeks• Darbepoetin α• Placebo• Hb = 13.0 g/dL--RCTMaddux et al. \[[@CR43]\], 2007, USAx26,244Follow-up period not standardized for all patients (patients followed until onset of dialysis, renal transplantation, disenrollment, study end, or death)• ESA-treated• ESA-Untreated patientsNA (not specified)--RetrospectivePapatheofanis et al. \[[@CR42]\], 2008, USAx1526 months• Epoetin α• Hb ≥ 11 g/dLMean Hb 12.2 g/dLRetrospectiveProvenzano et al. \[[@CR46]\], 2004, USAxx133816 weeks• Epoetin α• 11--12 g/dL• Hb 11.6 g/dLProspective single-arm trial, cohort studyRoger et al. \[[@CR48]\], 2014, Australia and Canadax5124 weeks (HRQoL assessment)• Darbepoetin α• Placebo• 13.0 g/dL• Hb: (darbepoetin α): 12.5 g/dL• Hb (placebo): 10.5 g/dLRCTRossert et al. \[[@CR49]\], 2006, Europe, Australia, Canada, and Israelx3904 months of stabilization followed by 36 months of maintenance• SC Epoetin α• High (Hb = 13.0--15.0 g/dL)• Low (Hb = 11.0--12.0 g/dL)High (men): 14.4 g/dLHigh (women): 13.4 g/dLLow (men): 12.1 g/dLLow (women): 11.4 g/dLRCTSingh et al. \[[@CR23]\], 2006, USA, Irelandxx143236 months• Epoetin α• Hb = 13.5 g/dL• Hb = 11.3 g/dL• Hb = 12.6 g/dL• Hb = 11.3 g/dLRCTWish et al. \[[@CR41]\], 2009, USAx37,105Follow-up period not standardized for all patients (patients followed until onset of dialysis, renal transplantation, disenrollment, study end, or death)Patients with or without anaemia, treated or not treated with ESAs (epoetin α, darbepoetin, and iron)NA (not specified)NA (not specified)Retrospective*AKDN* Alberta Kidney Disease Network, *EPO* erythropoietin, *ESA* erythropoiesis-stimulating agent, *Hb* haemoglobin, *HRQoL* health-related quality of life, *NA* not available (i.e. not assessed/reported in the study), *RCT* randomized controlled trial, *RHuEPO* recombinant human erythropoietin, *SC* subcutaneous

Interventions and Haemoglobin Targets {#Sec09}
-------------------------------------

ESA treatment was the intervention of interest in all included studies, including those with concomitant iron supplementation. No studies investigated RBCT (Table [1](#Tab1){ref-type="table"}). Haemoglobin targets ranged between 9.0 and 10.9 g/dL \[[@CR39]\] and 13.0--15.0 g/dL \[[@CR49]\]. Five studies (31.3%) did not specify a haemoglobin target \[[@CR14], [@CR16], [@CR38], [@CR41], [@CR43]\].

Geography {#Sec010}
---------

Studies were conducted across a range of geographical areas: six (37.5%) studies in North America exclusively \[[@CR16], [@CR39], [@CR41]--[@CR43], [@CR46]\], two (12.5%) in Europe exclusively \[[@CR14], [@CR38]\], and eight (50.0%) elsewhere (including international collaborations; Table [1](#Tab1){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}) \[[@CR23], [@CR37], [@CR40], [@CR44], [@CR45], [@CR47]--[@CR49]\]. Five of the six (83.3%) studies that reported on costs were conducted in North America \[[@CR39], [@CR41]--[@CR43], [@CR46]\]. Of the 13 studies that reported HRQoL outcomes, eight (61.5%) were conducted elsewhere (including international collaborations) \[[@CR23], [@CR37], [@CR40], [@CR44], [@CR45], [@CR47]--[@CR49]\], three (23.1%) were conducted in North America \[[@CR16], [@CR39], [@CR46]\] and two (15.4%) in Europe (Table [1](#Tab1){ref-type="table"}) \[[@CR14], [@CR38]\]. Among eight studies conducted in other or mixed locations, six (75.0%) were RCTs. For the three (18.8%) studies with data collected after 2011 \[[@CR14], [@CR47], [@CR48]\], two were international collaborations \[[@CR47], [@CR48]\] and one was conducted in Europe \[[@CR14]\].Fig. 3Regions. ^a^Includes international collaborations

Health-Related Quality of Life (HRQoL) Measurements Used {#Sec011}
--------------------------------------------------------

Among these 13 studies, the generic 36-Item Short-Form Survey (SF-36) was used in eight (61.5%) \[[@CR23], [@CR37], [@CR38], [@CR40], [@CR44], [@CR47]--[@CR49]\]; the Linear Analog Scale Assessment (LASA) \[[@CR23], [@CR46]\], Kidney Disease Questionnaire (KDQ) \[[@CR23], [@CR46]\], Kidney Disease Quality of Life (KDQoL) \[[@CR14], [@CR16]\], and Functional Assessment of Cancer Therapy (FACT)-Fatigue \[[@CR47], [@CR48]\], were each used in two (15.4%); and quality-adjusted life-years (QALYs) \[[@CR39]\], Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue \[[@CR40]\], EuroQoL-5 Dimensions (EQ-5D) \[[@CR47]\], and a customized approach \[[@CR45]\] were each used in one study. While QALYs are not a measure of HRQoL, they were considered as such as they provide insight into the incremental gains in HRQoL associated with a particular treatment.

Impact of Treatments on HRQoL {#Sec13}
-----------------------------

Six studies with sample sizes ranging between 45 and 4038 patients compared HRQoL outcomes in ESA-treated versus ESA-untreated patients \[[@CR14], [@CR40], [@CR45]--[@CR48]\]. In two placebo-controlled RCTs, HRQoL was generally improved by ESAs, although there were discrepancies observed between the statistical significance and clinical significance (MCID) of the results (Table [2](#Tab2){ref-type="table"}) \[[@CR47], [@CR48]\]. Two single-arm studies reported significant HRQoL improvements after ESA initiation compared with baseline \[[@CR45], [@CR46]\], and that reported by Provenzano et al. \[[@CR46]\] appeared clinically significant (i.e. MCID reached; Table [2](#Tab2){ref-type="table"}). The study by Hirakata et al. \[[@CR40]\] was an RCT designed to compare the impact of aiming for haemoglobin levels of 12--13 g/dL (with darbepoetin alfa) versus levels of 10--12 g/dL (with epoetin alfa). These levels were achieved after a 'dose--response' phase, during which patients in both cohorts achieved levels of 12 g/dL, and when HRQoL was assessed \[[@CR40]\]. The authors reported clinically and statistically meaningful improvements in HRQoL during the maintenance phase relative to baseline (Table [2](#Tab2){ref-type="table"}). In contrast, a cross-sectional study by Eriksson et al. \[[@CR14]\] found that ESA-untreated patients had higher HRQoL than ESA-treated patients (Table [2](#Tab2){ref-type="table"}).Table 2Summary of findings: health-related quality of lifeStudyTreated versus untreated patientsHigh versus low Hb target or Hb levelsAkizawa et al. \[[@CR37]\]--SF-36 • Vitality: higher for Hb = 11.0--13.0 g/dL (MCID reached, *P* \< 0.05)Clement et al. \[[@CR39]\]--QALYs gained (relative to no ESA treatment) • Hb = 9.0--10.9 g/dL: 0.65 • Hb = 11.0--12.0 g/dL: 0.51 • Hb \> 12.0 g/dL: 0.30De Goeij et al. \[[@CR38]\]--SF-36 • Bodily pain, vitality, social functioning, mental summary: lower for Hb \< 11 g/dL vs. Hb = 11.0--12.0 g/dL (MCID reached; *P* \< 0.05) • Physical functioning, physical summary: higher for Hb ≥ 13 g/dL than Hb = 11.0--12.0 g/dL (MCID reached; *P* \< 0.05) • General health: higher for Hb ≥ 13.0 g/dL than Hb = 11.0--12.0 g/dL, but not clinically meaningful (MCID not reached; *P* \< 0.05)Eriksson et al. \[[@CR14]\]KDQoL-36 (ESA/iron-treated vs. non-ESA/iron-treated patients) • Physical composite summary (stage 3 & 4), mental composite summary (stage 3 & 4): higher in non-ESA/iron-treated patients, but not clinically meaningful (MCIDs not reached; *P* \< 0.05)--Finkelstein et al. \[[@CR16]\]--KDQoL-36 • EQ-5D index (stage 3 and 4), symptom problem, effects kidney disease, burden of kidney disease, work status, sleep, symptom problem, effects kidney disease, burden kidney disease, work status, role---emotional, social function, energy/fatigue: increased with higher Hb levels (MCID reached; *P* \< 0.05) • Cognitive function: higher with high Hb levels, but not clinically meaningful (MCID not reached; *P* \< 0.05)Hirakata et al. \[[@CR40]\]SF-36 • Role-physical, general health, vitality: improved (MCID reached; *P* \< 0.05)FACIT-Fatigue • FACIT-Fatigue: improved (MCID reached; *P* \< 0.05)Islam et al. \[[@CR45]\]Customized approach • Normal sense of wellbeing, good appetite, normal physical activity: improved (MCID does not apply; *P* \< 0.05)--Kawaguchi et al. \[[@CR44]\]--SF-36 • No domains improved (MCID not reached; *P* \> 0.05)Lewis et al. \[[@CR47]\]SF-36 • Energy, physical function, role physical: higher in treatment arm, but not clinically meaningful (MCID not reached; *P* \< 0.05)FACT-Fatigue • FACT-Fatigue: higher in treatment arm, but not clinically meaningful (MCID not reached; *P* \< 0.05)EQ-5D • EQ-5D index: higher in treatment arm (MCID reached; *P* \< 0.05)--Provenzano et al. \[[@CR46]\]KDQ • Physical symptoms, fatigue, depression, relationship with others, frustration: improved (MCID reached, *P* \< 0.05)LASA • Energy, activity, overall QoL: improved (MCID reached; *P* \< 0.05)--Roger et al. \[[@CR48]\]SF-36 • Physical function, role-physical, bodily pain, physical component: higher in treatment arm (MCID reached; *P*s \< 0.05) • Vitality, social functioning, mental health: similar (MCID reached; *P* \> 0.05)FACT-Fatigue • Anaemia, and total score: higher in treatment arm (MCID reached; *P* \< 0.05) • Function: higher in treatment arm, but not clinically meaningful (MCID not reached, *P* \< 0.05)--Rossert et al. \[[@CR49]\]--SF-36 • Vitality: higher for Hb = 13.0--15.0 g/dL (MCID reached, *P* \< 0.05) • Physical function, physical role, emotional role: similar (MCID reached; *P* \> 0.05)Singh et al. \[[@CR23]\]SF-36 • Emotional role: higher for Hb target = 13.5 g/dL (MCID reached; *P* \< 0.05)LASA • No domains improved (MCIDs not reached; Ps \< 0.05)KDQ • Total score: similar (MCID reached; *P* \> 0.05)*EQ*-*5D* EuroQol-5 Dimensions, *ESA* erythropoiesis-stimulating agent, *FACIT* Fatigue Functional Assessment of Chronic Illness Therapy - Fatigue, *FACT* Fatigue Functional Assessment of Cancer Therapy - Fatigue, *Hb* haemoglobin, *KDQ* Kidney Disease Questionnaire, *KDQoL* Kidney Disease Quality of Life, *LASA* linear analogue self-assessment, *MCID* minimal clinically important difference, *QALY* quality-adjusted life-year, *QoL* quality of life, *SF*-*36* 36-item Short Form Health Survey

Five studies with sample sizes ranging between 25 and 1432 compared HRQoL among patients with high versus low haemoglobin treatment targets \[[@CR23], [@CR37], [@CR39], [@CR44], [@CR49]\]. Two studies with sample sizes ranging between 371 and 1186 assessed the HRQoL impact of having different haemoglobin levels \[[@CR16], [@CR38]\]. In two RCTs, 'vitality' (i.e. a domain measuring general energy/fatigue) was clinically and significantly higher in the high haemoglobin target group \[[@CR37], [@CR49]\], whereas other SF-36 domains showed marginal improvements of uncertain clinical significance (i.e. MCID often not reached; Table [2](#Tab2){ref-type="table"}). In another RCT, Singh et al. \[[@CR23]\] found non-significant improvements for patients randomized to achieve higher haemoglobin levels, except for the SF-36 domain 'emotional role'. Moreover, after 8 months of follow-up on ESA treatment that aimed to raise haematocrit levels to 36%, Kawaguchi et al. \[[@CR44]\] did not find significant differences in HRQoL relative to baseline (some patients may have been treated at baseline; Table [2](#Tab2){ref-type="table"}). A cost-utility analysis conducted by Clement et al. \[[@CR39]\] showed that gains in QALY relative to no treatment were smaller for haemoglobin targets of 11.0--12.0 g/dL and \> 12.0 g/dL compared with a haemoglobin target of 9.0--10.9 g/dL (Table [2](#Tab2){ref-type="table"}) \[[@CR39]\]. Two studies reported that higher haemoglobin levels were generally associated with improved overall HRQoL \[[@CR16], [@CR38]\].

Costs {#Sec14}
-----

Four studies with sample sizes ranging between 152 and 37,105 investigated the costs of treated versus untreated anaemia of CKD \[[@CR41]--[@CR43], [@CR46]\]. In a single-arm prospective study, Provenzano et al. \[[@CR46]\] reported that the proportion of patients who required RBCT decreased from 11.1 to 3.7% after initiating ESA treatment (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Using a retrospective cohort study design, Wish et al. \[[@CR41]\] found that patients with untreated anaemia incurred 17% higher direct costs than patients with treated anaemia (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Using a similar study design, Maddux et al. \[[@CR43]\] concluded that ESA-untreated patients incurred 22.8% higher direct costs than treated patients (Table [3](#Tab3){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). In a longitudinal retrospective study, Papatheofanis et al. \[[@CR42]\] reported healthcare cost savings of \$US4417 per patient per year after patients initiated ESA treatment (relative to baseline; Table [3](#Tab3){ref-type="table"}).Table 3Summary of findings: Costs^a^StudyTreated versus untreated patientsHigh versus low Hb target or Hb levelsClement et al. \[[@CR39]\]--Direct costs • Higher costs when aiming for an Hb target \> 12 g/dL relative to aiming for an Hb target = 9.0--10.9 g/dLMaddux et al. \[[@CR43]\]Direct costs• ESA-treated patients had lower total healthcare costs than ESA-untreated patients (\$US3876 vs. 4758 PPPM, *P* \< 0.05)--Papatheofanis et al. \[[@CR42]\]Direct costs• Total monthly employer costs (medical and pharmacy costs) fell from \$US1710.90 PPPM to \$US1342.79 after initiating EPO, yielding a \$US4417 PPPY decrease in costsIndirect costs• 91.5% increase in productivity (from 217 SKU/week \[1--3 months pre-EPO\] to 416 SKU/week \[4--6 months post-EPO\]) and 52.3 days PPPY decrease in absenteeism (from 2.82 days per week \[1--3 months pre-EPO\] to 3.91 days per week \[4--6 months post-EPO\]) after epoetin initiation relative to the pre-EPO period--Provenzano et al. \[[@CR46]\]HRU• The proportion of patients that required RBCT after initiating ESA treatment decreased from 11.1 to 3.7% (*P* \< 0.05)Singh et al. \[[@CR23]\]--HRU • 5.1% higher risk (32.6 vs. 27.5%) of having a hospitalization with a cardiovascular cause for patients randomized in the high Hb target group (*P* \< 0.05) • 5.0% higher risk (51.6 vs. 46.6%) of having a hospitalization for any cause for patients randomized in the high Hb target group (*P* \< 0.05)Wish et al. \[[@CR41]\]Direct costs• 17% higher overall costs for untreated patients (\$US4470 PPPM) than treated patients (\$US3806 PPPM)--*EPO* erythropoietin, *ESA* erythropoiesis-stimulating agent, *Hb* haemoglobin, *HRU* healthcare resource utilization, *PPPM* per patient per month, *PPPY* per patient per year, *RBCT* red blood cell transfusion, *SKU* Stock keeping units^a^Costs and cost differences presented in this table are presented as reported in the original publicationFig. 4Cost outcomes among studies that compared treated vs. untreated patients. *ESA* erythropoiesis-stimulating agent, *PPPM* per patient per month, *RBCT* red blood cell transfusion

Two studies with sample sizes ranging between 438 and 1432 compared the costs associated with aiming for higher and lower haemoglobin targets using ESAs \[[@CR23], [@CR39]\]. With respect to HRU, an RCT by Singh et al. \[[@CR23]\] reported that the proportion of patients with hospitalization for a cardiovascular cause was 5% higher in patients randomized to achieve a higher haemoglobin target than in patients randomized to achieve a lower haemoglobin target (Table [3](#Tab3){ref-type="table"}). In a cost-utility analysis, Clement et al. \[[@CR39]\] reported that the costs of aiming for a haemoglobin target \> 12 g/dL were higher than those of aiming for a target of 9.0--10.9 g/dL (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec15}
==========

The clinical guidelines and treatment landscape for the management of anaemia of CKD have substantially evolved in the past decade. Furthermore, regional differences in the disease management of CKD-related anaemia make it difficult to compare studies and summarize existing evidence across regions. Thus, a global updated assessment of the cost and HRQoL burden of anaemia of CKD is much needed. This SLR qualitatively assessed the cost and HRQoL burden of anaemia of CKD in patients with NDD-CKD in a narrative synthesis of 16 studies. All eligible studies focused on ESAs, and some also reported on iron as a concomitant treatment. In general, HRQoL benefits associated with higher haemoglobin targets appeared modest and of uncertain clinical significance \[[@CR16], [@CR37]--[@CR39], [@CR44], [@CR49]\]. However, improvements in the domain of 'vitality' were observed in two studies \[[@CR37], [@CR49]\]. Studies generally reported higher overall HRQoL in ESA-treated patients than in untreated patients \[[@CR45]--[@CR48]\], although one real-world study noted that ESA/iron treatment was associated with lower HRQoL \[[@CR14]\]. In addition, studies showed that aiming for higher versus lower haemoglobin targets was associated with higher HRU and costs, and lower gains in QALY \[[@CR23], [@CR39]\]. However, despite the high acquisition costs of ESAs, leaving anaemia of CKD untreated resulted in higher costs and HRU \[[@CR41]--[@CR43], [@CR46]\]; this finding highlights the importance of treating this condition from an economic standpoint. In summary, results from this narrative synthesis shed light on the unmet needs of patients with NDD-CKD and the substantial burden of current treatment.

Impact of Higher Haemoglobin Targets on HRQoL {#Sec16}
---------------------------------------------

Aiming for higher haemoglobin targets led to seemingly modest HRQoL benefits compared with aiming for lower targets. While there is a clear association between haemoglobin levels and HRQoL \[[@CR16], [@CR50]--[@CR52]\], treating patients to currently unachievable high levels of haemoglobin (not allowed per guidelines, high cost or lack of response) seems to have mitigated effects on HRQoL. The impact on fatigue-related domains appeared more pronounced in two RCTs, as 'vitality' was the only SF-36 domain with clinically and statistically meaningful improvements for patients randomized in higher haemoglobin target groups. The most significant HRQoL improvements ensuing from anaemia treatment are typically related to physical symptoms and fatigue, while other domains are more marginally improved \[[@CR53]\].

A study by Clement et al. \[[@CR39]\] reported on the impact of different haemoglobin targets on the QALYs and costs of patients with anaemia of CKD. With respect to QALYs, the authors found that the gains in QALY became more limited when aiming for haemoglobin targets above 12 g/dL. Similar results were obtained in a more recent cost-effectiveness analysis by Yarnoff et al. \[[@CR54]\], which was not included in the present study since it did not focus on the impact of a particular treatment. Together, these findings may reflect the higher risks of MACE associated with ESAs and the high doses of ESAs required to achieve high haemoglobin levels.

Among the pivotal trials that included HRQoL assessments, the CHOIR trial found non-statistically significant improvements in HRQoL, whereas the CREATE trial reported HRQoL improvements across all SF-36 domains assessed \[[@CR22], [@CR23], [@CR55]\]. Part of this discrepancy might be explained by the fact that the CHOIR trial, unlike the CREATE trial, censored patients at KRT initiation (i.e. some patients became DD during the course of the study period). This also explains the exclusion of CREATE in the current SLR, as patients were not NDD throughout the complete duration of follow-up. Another difference that may contribute to this discrepancy is that patients included in the CHOIR trial had lower baseline haemoglobin levels and required ESA doses twice as high as those used in the CREATE trial to achieve similar haemoglobin levels.

Impact of Treatment of Anaemia on HRQoL {#Sec17}
---------------------------------------

Two RCTs and two single-arm trials assessed the HRQoL impact of treating anaemia of CKD compared with non-treatment. In general, clinically meaningful improvements in HRQoL were achieved following treatment of anaemia of CKD with ESAs. A noteworthy exception is the cross-sectional study conducted by Eriksson et al. \[[@CR14]\], who reported better HRQoL among ESA-untreated/iron-untreated than ESA and/or iron-treated patients. Furthermore, there may be differences between the recommended management of anaemia of CKD practiced during an RCT and that observed in clinical practice as reported in the cross-sectional study. Due to the limited number of eligible real-world studies (only three) that investigated HRQoL, it is challenging to confirm this hypothesis. Further research is warranted to address the paucity of real-world data on the HRQoL of patients with NDD-CKD.

Collister et al. \[[@CR34]\] recently published a meta-analysis reviewing the impact of ESAs on the HRQoL of patients with anaemia of CKD. The authors did not find clinically or statistically significant differences in HRQoL associated with higher haemoglobin targets, which has been interpreted as an absence of meaningful positive impact of ESAs on HRQoL. The results from the present SLR suggest a more cautious conclusion should be drawn: ESAs do have an impact on HRQoL when ESA-treated patients are compared with their untreated counterparts. However, relative to aiming for lower haemoglobin targets, ESA treatment with high haemoglobin targets provides, at best, modest HRQoL benefits. This may be partially explained by the inclusion of study designs other than RCTs in the current SLR, such as prospective observational studies, prospective single-arm trials, and retrospective studies.

With respect to the impact of iron treatment on HRQoL, only one study matching our search criteria investigated this question, and it focused on the effects of oral versus intravenous iron treatment. The authors found higher improvements in KDQ scores for patients treated with intravenous iron. Both routes of administration led to improvements in haemoglobin levels that appeared much smaller than those commonly observed with ESAs (i.e. oral: + 0.2 g/dL, intravenous: + 0.4 g/dL) \[[@CR56]\].

Impact of Higher Haemoglobin Targets on Costs {#Sec18}
---------------------------------------------

With respect to costs, the cost-utility analysis conducted by Clement et al. \[[@CR39]\] found that gains in QALYs associated with haemoglobin targets above 12 g/dL required much higher costs, a conclusion also drawn by Yarnoff et al. \[[@CR54]\]. This may be explained by a higher incidence of MACE when aiming for such targets. In support of this hypothesis, one RCT included in the present review found that patients randomized to achieve a higher haemoglobin target with ESAs had higher HRU \[[@CR23]\].

Impact of Treatment of Anaemia on Costs {#Sec19}
---------------------------------------

Four included studies consistently showed that the non-treatment of anaemia of CKD is associated with higher HRU and costs. One study by Provenzano et al. \[[@CR46]\] showed that untreated patients had higher HRU than ESA-treated patients, and three studies showed that non-treatment was associated with significantly higher costs than was treatment \[[@CR41]--[@CR43]\]. Notably, the study by Provenzano et al. \[[@CR46]\] was prospective, whereas the three other studies that reported on costs had a retrospective design, which further highlights the robustness of these conclusions with regards to study designs. Collectively, this suggests that, within the current standard of care framework, the higher acquisition costs of ESAs are offset by lower medical costs \[[@CR41], [@CR43]\].

As a cost-lowering alternative, epoetin biosimilars have been available in Europe since 2007 \[[@CR57]\], and RETACRIT^®^ became the first approved epoetin biosimilar in the USA in mid-2018. Biosimilars were estimated to have led to savings representing 15--30% of the price of the reference agent \[[@CR58]\], suggesting savings of similar magnitude can be anticipated with biosimilar ESAs. Presumably due to initial safety, efficacy, and manufacturing concerns experienced in poorly regulated countries, biosimilars do not have a good reputation among certain providers and regulators. This likely accounts for the apparent underuse of biosimilar epoetin in some European countries \[[@CR59], [@CR60]\], which limits our understanding of how this may affect healthcare costs for anaemia of CKD.

Limitations {#Sec20}
-----------

Findings of this literature summary review should be considered in light of several limitations. First, some studies may have been missed despite the scope of the rigorous search strategy used in the current SLR. For instance, studies that focused on 'treatments' as a whole, and did not specify the names of specific treatments, may not have been identified by the electronic search strategy. Second, because studies were heterogeneous in terms of study designs and choices of outcomes (e.g. choice of HRQoL measurements, HRQoL domains reported, HRU vs. costs reported, etc.), this review could not quantitatively summarize study conclusions using a meta-analysis. Third, while a rigid cut-off derived from the literature was applied to HRQoL findings, an MCID should ideally be determined using study-specific elements. For instance, studies that included patients with better baseline performance status are less likely to report higher improvements due to a ceiling effect, which shows the importance of adapting the MCID to each study \[[@CR61]\]. Finally, the risk of bias and quality of reporting were not assessed because of the high heterogeneity in study designs.

Conclusion {#Sec21}
==========

In this literature review, non-treatment of patients with anaemia of CKD who were not on dialysis resulted in higher costs and was associated with poorer HRQoL, which emphasizes the need for treatment. However, aiming for haemoglobin targets higher than 12 g/dL led to seemingly modest HRQoL improvements of uncertain clinical significance, although improvements in the vitality domain appeared more robust than those in other domains. Effective treatment options with improved safety profiles are needed to improve the HRQoL of these patients with anaemia of CKD.

Appendix 1: Search Strategy {#Sec22}
===========================

1Dialysis or h?emodialysis or h?emofiltration or h?emodiafiltration or endstage renal or endstage kidney or end-stage renal or end-stage kidney or ESRF or ESKF or ESRD or ESKD or chronic kidney or chronic renal or CKF or CKD or CRF or CRD or CAPD or CCPD or APD or predialysis or pre-dialysis or ur?emi\$674,4632((Kidney or renal) and disease) or ((Kidney or renal) and insufficiency) or ((Kidney or renal) and dysfunction) or ((Kidney or renal) and failure) or (Exp kidney disease/) or (Exp renal disease/) or (Exp kidney insufficiency/) or (Exp kidney dysfunction/) or (Exp kidney failure/)1,637,7303An?emia or (Exp anemia/)564,6884economic OR cost OR burden OR landscape OR caregiver OR indirect OR "quality of life" or "qol" or "HRQOL" or "patient-reported outcome"2,886,6075erythropoiesis-stimulating agent\$ or erythropoiesis stimulating agent\$ or "ESA" or epoetin or epoetin alfa or Epogen or Procrit or darbepoetin or darbepoetin alfa or Aranesp18,5356blood transfusion or (exp blood transfusion/) or red blood cell\$ transfusion277,8847Iron or ferrous or ferric or (Exp iron/)507,9888(1 or 2)1,873,5419(1 or 2) filter humans1,497,72410(1 or 2) filter humans and 386,39611(1 or 2) filter humans and 3 and 4955512(1 or 2) filter humans and 3 and 4 and (5)14201312 de-duplicated, in English, from 2000 onwards7931413 excluding letters, interviews, editorials, comments, biographies, and addresses6311514 restricted to adult populations25016(1 or 2) filter humans and 3 and 4 and (5 or 6)22301716 de-duplicated, in English, from 2000 onwards14151817 excluding letters, interviews, editorials, comments, biographies, and addresses10901918 restricted to adult populations45820(1 or 2) filter humans and 3 and 4 and (5 or 6 or 7)33852120 de-duplicated, in English, from 2000 onwards21282221 excluding letters, interviews, editorials, comments, biographies, and addresses1625(1) Search conducted on 17 March 2017(2) Search conducted in MEDLINE, MEDLINE In-Process, Embase, CENTRAL, CDSR, NHS EED and NHS HTA using OvidSP(3) Search conducted using ".MP" field in OvidSP, which searches title, original title, abstract, subject heading, name of substance, and registry word fields

Appendix 2: List of extracted variables {#Sec23}
=======================================

Author(s)Year of publicationTitleIntervention(s) (i.e. ESAs, and/or RBCT and/or iron/ferric supplementation)Country(ies) in which the study was conductedStudy designTime period of data collection analysisHb target/guideline(s) followedDates of data collectionDose/dosing scheduleTreatment durationEligibility criteria (i.e. inclusion and exclusion criteria)Number of patients included in the analysisPatient characteristics at study initiation (i.e. mean age, sex, CKD stage, type of dialysis and months on dialysis, comorbidities, and laboratory measurements)HRQoL outcomes (measured with KDQoL-36 and KDQoL-12, SF-36 and SF-12, QALYs, fatigue score, 6-minute walking test, physical activity, KDQ-13, KDQ-26, other measurements)Cost outcomes (HRU, cost per QALY, treatment-related costs, other direct costs, and indirect costs)

Appendix 3: Minimal clinically important difference thresholds used to determine the clinical significance of HRQoL changes in the narrative synthesis {#Sec24}
======================================================================================================================================================

QuestionnaireDisease-specific (yes/no, disease and population name)Populations where validated (DD/NDD)Typical range of MCIDMCID value used as thresholdReferencesSF-12/36NoDD3--54Leaf 2009 Kidney Int 75: 15--24Eriksson 2017 Nephrol Dial Transpl 32(12):2106--11KDQoL-12/36Yes, CKDDD3--54Leaf 2009 Kidney Int 75: 15--24Eriksson 2017 Nephrol Dial Transpl 32(12):2106--11KDQYes, CKDDD0.50.5Leaf 2009 Kidney Int 75: 15--24EQ-5DNo--0.06--0.080.07Leaf 2009 Kidney Int 75: 15--24LASANo--10--2015Cella 2002 J Pain Symp Man 24: 547--561FACIT-Fatigue scaleHybrid (targeted and specific)Iron-deficiency anemia (in general)3.03.0Bohannon 2016 J Eval Clin Pract 23(2):377--381FACT-Fatigue scaleYes, cancer--3.03.0Leaf 2009 Kidney Int 75: 15--24Eriksson 2017 Nephrol Dial Transpl 32(12):2106--11*CKD* chronic kidney disease, *DD* dialysis dependent, *EQ*-*5D* EuroQol-5 Dimensions, *FACIT* Fatigue Functional Assessment of Chronic Illness Therapy-Fatigue, *KDQoL* Kidney Disease Quality of Life, *LASA* linear analogue self-assessment, *MCID* minimal clinically important difference, *NDD* non-dialysis-dependent, *SF*-*12/36* 12- or 36-item Short Form Health Survey
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